AMETEK, Inc. (AME) Stock Price Today
Aura AI Summary
Key Stats
- $54.51BMarket Cap
- -Volume
- IndustrialsSector
- $258.5252W High
- $179.2852W Low
- -Typical Hold Time
- $56.05BEnterprise Value
- 0.57%Div Yield
- -Trading Activity
Track AMETEK, Inc. (AME) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, AMETEK, Inc. has traded between a low of $179.28 and a high of $258.52, highlighting its annual price range. Buy and sell AMETEK, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Most Recent News
Novartis shares plunge 12.5% after two Phase 3 drug trials fail primary goals
Novartis shares dropped over 12.5% after its Phase 3 HARBOR trial for del-desiran and Phase 3 HORIZON trial for pelacarsen both failed to meet primary endpoints. These failures mean the drugs did not show significant benefits over placebo for their t...
Levi & Korsinsky probes lululemon over tariff refund disclosures after earnings and guidance cuts.
Levi & Korsinsky is investigating lululemon athletica for potentially misleading disclosures about a $134.5 million federal tariff refund included in its recent quarterly earnings. The refund boosted earnings per share by $0.86 and operating margins,...
Structure Therapeutics shows strong obesity drug results, remains a strong buy with $1.3B cash runway.
Structure Therapeutics reported promising 72-week data for its oral obesity drug aleniglipron, showing 16.2% weight loss with low adverse event discontinuations and no liver injury. The company also advanced ACCG-2671, an oral amylin agonist with hum...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.